2014
Outcomes and toxicity of SBRT for patients with unresectable pancreatic adenocarcinoma.
Pollom E, Alagappan M, Chan C, Shultz D, Kunz P, Koong A, Chang D. Outcomes and toxicity of SBRT for patients with unresectable pancreatic adenocarcinoma. Journal Of Clinical Oncology 2014, 32: 317-317. DOI: 10.1200/jco.2014.32.3_suppl.317.Peer-Reviewed Original ResearchStereotactic body radiotherapyUnresectable pancreatic adenocarcinomaGy x 5Pancreatic adenocarcinomaPrior RTCurrent chemoResectable diseaseTumor locationTime of SBRTToxicity of SBRTLocal controlBorderline resectable diseaseGood local controlUse of chemotherapyDate of diagnosisCommon treatment regimensBetter OSMedian OSOS ratesAdvanced diseaseGI toxicityCumulative incidenceLocal recurrenceBody radiotherapyTreatment regimens
2010
18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy
Schellenberg D, Quon A, Minn AY, Graves EE, Kunz P, Ford JM, Fisher GA, Goodman KA, Koong AC, Chang DT. 18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2010, 77: 1420-1425. PMID: 20056345, DOI: 10.1016/j.ijrobp.2009.06.049.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntimetabolites, AntineoplasticCA-19-9 AntigenDeoxycytidineDisease-Free SurvivalFluorodeoxyglucose F18GemcitabineHumansMiddle AgedMultivariate AnalysisPancreatic NeoplasmsPositron-Emission TomographyRadiopharmaceuticalsRadiosurgeryRadiotherapy DosageRetrospective StudiesConceptsMetabolic tumor burdenStereotactic body radiotherapyPancreas cancer patientsPositron emission tomographyMedian survivalCancer patientsOverall survivalMultivariate analysisHigh metabolic tumor burdenMaximum standardized uptake valueAdvanced pancreas cancerProgression-free survivalGemcitabine-based chemotherapyLength of survivalStandardized uptake valuePET scan parametersProgression-FreeChemotherapy cyclesHigher SUVmaxIndependent predictorsTumor burdenBody radiotherapyPancreas cancerPrognostic valueMedian SUVmax
2008
Phase II Trial of Single Fraction Stereotactic Body Radiotherapy Delivered by Trilogy Linear Accelerator for the Treatment of Locally Advanced Adenocarcinoma of the Pancreas
Schellenberg D, Kim J, Columbo L, Lee C, Fisher G, Kunz P, Maxim P, Goodman K, Chang D, Koong A. Phase II Trial of Single Fraction Stereotactic Body Radiotherapy Delivered by Trilogy Linear Accelerator for the Treatment of Locally Advanced Adenocarcinoma of the Pancreas. International Journal Of Radiation Oncology • Biology • Physics 2008, 72: s127. DOI: 10.1016/j.ijrobp.2008.06.428.Peer-Reviewed Original Research